GSK

The multinational pharma company will now be able to access Tempus' de-identified patient data.

It follows the clearance for connecting Hailie with AstraZeneca's Symbicort inhaler.

The multiyear agreement will focus on speeding clinical trials and drug development in oncology and nonalcoholic steatohepatitis.

Also: Truepill launches a COVID-19 test coverage platform for insurers, and 23andMe extends its partnership with GSK.

The partnership expands on the companies’ earlier collaboration announced in late 2019.

The partnership aims to investigate the role genetics play in developing personalised cancer treatments

The £40 million system is intended to enable researchers to tackle the most pressing medical challenges.

Earnings reports shared by neurostimulation and digital medicine company NeuroMetrix during a Q2 investors’ call showed a slight drop in total revenue as the company is preparing to place its marketing weight behind the launch of its updated wearable pain relief product, Quell.